Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Exscientia Ltd ADR (NQ: EXAI ) 5.060 -0.240 (-4.53%) Official Closing Price Updated: 4:15 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Exscientia Ltd ADR < Previous 1 2 3 4 Next > AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week September 15, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th September 10, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... Via Talk Markets Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! September 05, 2024 The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... Via Talk Markets Topics Economy Exposures Economy Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week August 27, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. Via Talk Markets The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. August 18, 2024 Merging with a former rival will bolster its capabilities. Via The Motley Fool EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q2 2024 August 15, 2024 EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. Via InvestorPlace AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD August 14, 2024 The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... Via Talk Markets Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia? August 11, 2024 The leading company pioneering artificial intelligence (AI)-fueled drug discovery could get much bigger. Via The Motley Fool Topics Artificial Intelligence Exposures Artificial Intelligence AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals August 08, 2024 Exscientia merges with Recursion Pharmaceuticals in an all-stock deal. The new entity, named Recursion, will focus on industrializing drug discovery with advanced AI technologies, boasting $850 million... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD July 30, 2024 The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. Via Talk Markets AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD July 18, 2024 To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... Via Talk Markets Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD July 14, 2024 The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... Via Talk Markets 3 Small-Cap Stocks With Explosive 2X Growth Potential July 08, 2024 Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. Via InvestorPlace Clinical-Stage BioTech Drug Stocks Declined 13% In June July 01, 2024 Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read Via Talk Markets Largest Clinical-Stage BioTech Drug Stocks Declined 6% June 22, 2024 Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th June 17, 2024 The global Via Talk Markets AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week June 10, 2024 The global Via Talk Markets The 7 AI Categories Were Down 4%, On Average, This Week; Up 1% In May June 01, 2024 The 7 AI categories we track dropped, down 4.3% this week, and are now only up 1.3% for the month of May. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence 7 Underappreciated Stocks With 25% Return Potential in 2024 May 30, 2024 Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention. Via InvestorPlace The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035 May 23, 2024 One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Here are three. Via InvestorPlace EXAI Stock Earnings: Exscientia Beats EPS, Misses Revenue for Q1 2024 May 21, 2024 EXAI stock results show that Exscientia beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In May 20, 2024 The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence All 7 Artificial Intelligence (AI) Categories Reversed Direction This Week May 18, 2024 All 7 of the AI categories we track were up 2.9%, on average, this week. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence 7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs May 16, 2024 AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week May 13, 2024 Via Talk Markets Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May May 05, 2024 We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. Via Talk Markets Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday April 29, 2024 Via Benzinga The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD April 15, 2024 The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Six Of Seven AI Stock Categories Increased This Week March 23, 2024 All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial... Via Talk Markets Topics Artificial Intelligence Exposures Artificial Intelligence Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session April 03, 2024 Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... Via Benzinga Exposures Glyphosate < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.